Skip to content

Korea Equity Lens

  • About
  • IR Room
  • Research
    • Semiconductors
    • Bio & Healthcare
    • Defense
    • EV & Battery
    • Automotive
    • Energy
    • Robotics
    • Shipbuilding
  • Toggle search form
  • [Research] LIG D&A (079550) – Hana Securities | 4Q25 Miss · Solid Order Backlog · Medium-to-Long-term Fundamentals / 2026-02-19 Research
  • [Research] LIG D&A (079550) – Hana Securities | 1Q26 Earnings Beat · Backlog Re-rating · High-margin Follow-on Services / 2026-05-08 Research
  • [Research] Samsung SDI (006400) – Kiwoom Securities | Quarterly Turnaround · ESS LFP Ramp-up · Europe EV Market Share / 2026-07-31 Research
  • [Research] LigaChem Biosciences (141080) – iM Securities | Platform Valuation · Pipeline Milestones · Deal Expansion / 2025-08-12 Research
  • [Research] SK hynix (000660 / SKHY) – Mirae Asset | Server CPU Demand · HBM Diversification · HBM4 / 2026-05-07 Research
  • [IR] Samsung Electronics (005930) – Q1 2024 Earnings Presentation / 2024-04-30 IR Room
  • [Research] Alteogen (196170) – Hana Securities | Steady Milestone Inflows · Interpreting GSK’s Enhanze Deal · PGR Final Ruling Catalysts / 2026-05-13 Research
  • [Research] Samsung Biologics (207940) – Mirae Asset | Plant 5 Ramp-up · CDMO Expansion · Earnings Forecast / 2026-07-27 Research

[Research] LIG D&A (079550) – Eugene Investment & Securities | Global Demand Spillover · CapEx Expansion · Long-term Compounding / 2026-08-07

Posted on August 7, 2026August 21, 2026 By ksb220805@gmail.com

Brokerage : Eugene Investment & Securities

Analyst : Seungyun Yang

Investment Rating : BUY (Maintain)

Target Price : KRW 1,200,000 (Maintain)

Core Momentum : Multi-year earnings and margin expansion driven by Cheongung-II exports, production capacity additions across Gumi and Gimcheon facilities, and projected 40% operating profit CAGR over 2027-2028

1. [Valuation & Key Financial Metrics]

  • Investment Rating & Target Price: Rating BUY (Maintain), Target Price KRW 1,200,000 (Maintain), Current Price KRW 702,000 (As of 2026-08-06)
  • Guidance & Forecast Revisions:
    • Raised full-year corporate OPM guidance from 7% to 8% (annual revenue CAGR target of 15%)
    • 2026E operating profit revised upward to KRW 428 Billion (from KRW 421 Billion); 2027E operating profit maintained at KRW 596 Billion
  • Financial Forecasts & Historicals:
    • 2025A: Revenue KRW 4,307 Billion, Operating Profit KRW 319 Billion, Pre-tax Profit KRW 278 Billion, Net Profit KRW 237 Billion, EPS KRW 11,516 (Growth +15.5%), PER 36.6x, ROE 19.2%, PBR 6.5x, EV/EBITDA 22.9x
    • 2026E: Revenue KRW 4,992 Billion, Operating Profit KRW 428 Billion, Pre-tax Profit KRW 409 Billion, Net Profit KRW 322 Billion, EPS KRW 15,278 (Growth +32.7%), PER 45.9x, ROE 21.5%, PBR 9.1x, EV/EBITDA 28.3x
    • 2027E: Revenue KRW 6,023 Billion, Operating Profit KRW 596 Billion, Pre-tax Profit KRW 558 Billion, Net Profit KRW 475 Billion, EPS KRW 22,690 (Growth +48.5%), PER 30.9x, ROE 25.9%, PBR 7.2x, EV/EBITDA 21.3x
  • Stock Metrics: Market Cap KRW 15,444 Billion, Outstanding Shares 22,000 Thousand shares, 52-Week High/Low KRW 1,118,000 / KRW 360,000, 52-Week Daily Beta -0.25, 60-Day Avg Daily Trading Value KRW 179.7 Billion, Foreign Ownership 26.7%, Dividend Yield (2026E) 0.4%, Major Shareholders LIG & 9 affiliated parties (38.2%), National Pension Service & 1 affiliated party (10.3%)

2. [Market Opportunities & Business Outlook]

  • 2Q26 Earnings Review:
    • Consolidated revenue reached KRW 1,110.1 Billion (+17.4% YoY, -4.9% QoQ) and operating profit recorded KRW 105.7 Billion (+29.5% YoY, -38.2% QoQ, OPM 9.5%), broadly meeting consensus (KRW 110.5 Billion operating profit).
    • Profitability improved YoY backed by an expanding export mix, operating leverage, and the absence of one-off losses.
    • 2Q export sales reached KRW 281.8 Billion (+71.1% YoY, 25.4% of total revenue) with UAE Cheongung-II revenue contributing ~KRW 99 Billion. Export margins are estimated in the mid-20% range.
    • UAE shipments are anticipated to re-expand in Q3 and Q4.
  • Order Backlog & Regional Pipeline Expansion:
    • Order backlog stood at KRW 24.6 Trillion at the end of 2Q26 (+KRW 1.1 Trillion YoY).
    • In the Middle East, initial adoptions are stimulating demand across neighboring nations; Southeast Asian defense procurement interest is rising (with potential for faster contract execution than Middle Eastern follow-ons); and European outreach continues alongside Rheinmetall partnerships to penetrate NATO-centric procurement channels.
  • Manufacturing CapEx Expansion:
    • Expanding production and R&D capacity to fulfill contracts across three Middle Eastern customer nations, including new construction at the Gumi site and expansion of the Gimcheon facility (full revenue contribution expected post-2028).
    • 2027–2028 operating profit CAGR projected at 40%.

Editor’s Comment (Perspective)

The covering analyst views LIG D&A not as a company bounded by quarterly delivery base effects, but as an advancing defense exporter entering a compounding growth trajectory driven by global air defense demand spillovers and scheduled production across three Middle Eastern customer nations. This perspective places primary importance on the raised full-year OPM guidance, facility expansions across Gumi and Gimcheon securing long-term execution post-2028, and a projected 40% operating profit CAGR across 2027–2028 over near-term quarterly delivery variations.

To verify whether this investment thesis continues to materialize, primary focus should be directed toward the sequential rebound of UAE Cheongung-II deliveries in 3Q–4Q26, new contract awards across Southeast Asia and Eastern Europe (via the Rheinmetall partnership), and the operational progress of Gumi and Gimcheon facility expansions sustaining the 40% operating profit CAGR across 2027–2028. These milestones can be tracked via upcoming quarterly earnings releases, corporate IR disclosures, contract award filings, and official periodic reports.

📢 Disclaimer & Source

Source: This content has been structured and newly written based on officially disclosed financial facts and data from brokerage reports.

Investment Risk Notice: This content is provided for informational and linguistic reference purposes only. Under no circumstances does it constitute financial advice or a recommendation to buy or sell any specific securities. All investment decisions and financial responsibilities rest entirely with the investor.

Contact: Compliance and Copyright Inquiries (ksb220805@gmail.com)

Search by
Company Name or Stock Ticker.
Research, Defense

Post navigation

Previous Post: [Research] LIG D&A (079550) – Yuanta Securities | Cheongung-II Demand Surge · OPM Guidance Upgrade · Middle East Overlap / 2026-08-07
Next Post: [Research] LIG D&A (079550) – Shinhan Securities | Structural Export Growth · Order Pipeline · Long-term Demand / 2026-08-07

Related Posts

  • [Research] LIG D&A (079550) – Kiwoom Securities | Order Visibility · Production Expansion · Middle East Deliveries / 2026-08-07 Research
  • [Research] LigaChem Biosciences (141080) – Yuanta Securities | Payload Chemistry · Safety Profile · Differentiation / 2025-05-22 Research
  • [Research] SK hynix (000660 / SKHY) – Mirae Asset | ADR Listing · SOX Inclusion · HBM Pricing / 2026-06-25 Research
  • [Research] Alteogen (196170) – Shinhan Securities | Halozyme Patent Invalidated · Key Overhangs Materially Eased · Target Price Raised / 2026-05-14 Research
  • [Research] SK hynix (000660 / SKHY) – Shinhan | Memory ASP · Supply Tightness · Pricing Power / 2026-01-30 Research
  • [Research] Samsung SDI (006400) – Shinhan Securities | Profit Turnaround · ESS Margin Support · North America LFP Ramp-up / 2026-07-20 Research
  • [Research] LigaChem Biosciences (141080) – Mirae Asset Securities | Clinical Readouts · Pipeline Valuation · SOTP / 2026-01-26 Research
  • [Research] LIG D&A (079550) – Daishin Securities | 2Q26 Review · Backlog Realization · Export Margin Expansion / 2026-08-10 Research
  • [Research] SK hynix (000660 / SKHY) – DS Investment | Memory ASP · High-Value Product Mix · Supply Tightness / 2026-04-23 Research
  • [Research] Alteogen (196170) – Shinhan Securities | Halozyme Patent Invalidated · Key Overhangs Materially Eased · Target Price Raised / 2026-05-14 Research
  • [Research] SK hynix (000660 / SKHY) – SK Securities | Supply Tightness · LTA · Shareholder Returns / 2026-07-30 Research
  • [Research] Samsung Biologics (207940) – Yuanta Securities | US Site Acquisition · Biosecure Act Beneficiary · Plant 6 & Campus 3 Expansion / 2026-01-07 Research
  • [Research] Samsung Biologics (207940) – IBK Securities | Plant 5 PPQ Revenue · US Site Consolidation · Guidance Revision Potential / 2026-04-23 Research
  • [Research] Samsung Biologics (207940) – Shinhan Securities | Capacity Expansion · Peptide Entry · Guidance Upgrade / 2026-07-24 Research

Copyright © 2026 Korea Equity Lens.

Powered by PressBook News Dark theme